Clearside Biomedical (NASDAQ:CLSD) Given Buy Rating at Chardan Capital

Chardan Capital restated their buy rating on shares of Clearside Biomedical (NASDAQ:CLSD) in a research note published on Monday, Benzinga reports. The firm currently has a $6.00 price target on the stock.

A number of other brokerages have also recently commented on CLSD. Needham & Company LLC increased their target price on shares of Clearside Biomedical from $4.00 to $6.00 and gave the company a “buy” rating in a research report on Thursday, October 10th. HC Wainwright reissued a “buy” rating and issued a $5.00 target price on shares of Clearside Biomedical in a research note on Tuesday, August 27th. Finally, Oppenheimer initiated coverage on Clearside Biomedical in a research report on Tuesday, June 25th. They issued an “outperform” rating and a $5.00 price target for the company. One research analyst has rated the stock with a sell rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat, Clearside Biomedical has an average rating of “Moderate Buy” and a consensus target price of $5.17.

Clearside Biomedical Stock Up 2.7 %

CLSD opened at $1.15 on Monday. The company has a market cap of $85.94 million, a PE ratio of -2.09 and a beta of 2.35. Clearside Biomedical has a twelve month low of $0.65 and a twelve month high of $2.12. The company has a 50-day moving average price of $1.16 and a 200 day moving average price of $1.22.

Clearside Biomedical (NASDAQ:CLSD) last released its earnings results on Monday, August 12th. The company reported ($0.10) earnings per share for the quarter, beating the consensus estimate of ($0.14) by $0.04. The firm had revenue of $0.09 million during the quarter, compared to analysts’ expectations of $0.25 million. During the same quarter last year, the business earned ($0.15) EPS. As a group, sell-side analysts expect that Clearside Biomedical will post -0.56 earnings per share for the current year.

Institutional Trading of Clearside Biomedical

Several hedge funds have recently made changes to their positions in the company. Assenagon Asset Management S.A. acquired a new position in Clearside Biomedical in the second quarter valued at approximately $368,000. Vanguard Group Inc. lifted its stake in shares of Clearside Biomedical by 14.5% in the 1st quarter. Vanguard Group Inc. now owns 2,490,796 shares of the company’s stock valued at $3,811,000 after purchasing an additional 314,480 shares during the last quarter. International Assets Investment Management LLC acquired a new position in shares of Clearside Biomedical in the 1st quarter valued at $57,000. XTX Topco Ltd grew its holdings in shares of Clearside Biomedical by 172.2% during the 2nd quarter. XTX Topco Ltd now owns 54,313 shares of the company’s stock worth $71,000 after purchasing an additional 34,359 shares during the period. Finally, SG Americas Securities LLC acquired a new stake in shares of Clearside Biomedical during the 1st quarter worth about $49,000. Hedge funds and other institutional investors own 18.75% of the company’s stock.

About Clearside Biomedical

Clearside Biomedical, Inc, a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD.